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Summary Ninety percent of vocal fold cancers take the form of squamous cell carcinoma.
Since the 1980s, incidence in France has been constantly falling in males while increasing in
females. The main risk factor is smoking, alcohol being less implicated than in other laryngeal
or extralaryngeal locations. Vocal fold squamous cell carcinoma generally develops on healthy
mucosa, although primary precancerous lesions such as leukoplakia or papillomatous keratosis
are also frequent. The tumor usually originates in the non-lymphophilic mucosal free edge of
the vocal fold then invades the various anatomic subunits of the larynx, acquiring lymph-node
metastatic potential. Dysphonia is the ﬁrst presenting symptom, initially caused by defective
mucosal vibration and then by impaired mobility and ﬁnally ﬁxation of the vocal fold. Exten-
sion, risk factor and pretreatment assessments are as in other upper-aerodigestive-tract cancer
locations. The possibilities of laryngoscopic exposure and the tumor limits, however, need to
be precisely determined if transoral resection is to be considered. For small tumors, surgery or
exclusive radiation therapy can be suggested to the patient as part of an individual treatment
plan, each having its advantages and drawbacks. Cutting-edge teams report 5-year local control
rates of 85—95% in T1-class tumor and 60—90% in T2. Whatever the treatment option, smoking
cessation, close surveillance and cardiovascular prevention enable screening of other oncologic
locations and limit onset of the other pathologies implicated in most deaths.
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Introduction
Half of laryngeal cancers involve the vocal folds [1]. Histo-
logically, more than 90% of vocal fold cancers are squamous
cell carcinomas [2].
The situation and function of the vocal folds in the larynx
and upper aerodigestive tract make the clinical manifesta-
tions of glottic cancer signiﬁcant. Management takes full
advantage of all of the complementary examinations and
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herapeutic arsenal presently available in modern oncology,
ith the aim of obtaining cure and conserving the patient’s
hysical and psychological integrity [3].
pidemiology
ncidencehe epidemiological data presented here are for laryn-
eal cancer: no data speciﬁc to vocal fold cancer could be
etrieved, although it constitutes about a half of laryngeal
ancers [1].
served.
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tigure 1 Laryngeal cancer: incidence and mortality (male,
emale) according to age (yrs) in 2005.
In males, the incidence of laryngeal cancer is highest
n Southern Europe (Italy, Spain, France), some countries
f Central and Eastern Europe (Croatia, Slovakia, Poland,
elarus), and of South America (Argentine, Uruguay, Cuba)
nd in the African American population of the USA. In these
opulations, standardized incidence per 100,000 was around
0 in 2005. In females, the highest rate is found in the
frican American population, at around 3/100,000.
In France, with an estimated 3735 new cases in 2005
Fig. 1), 87% of which in males, laryngeal cancer is the 19th
ost common form of cancer. It constitutes 1.2% of cancers
s a whole, ranking 13th in frequency in males and 22nd in
emales. Standardized incidence is 7.1 in males and 1.0 in
emales: sex ratio, 7.1 [1].
With 1406 deaths, 89% of which in males, it is the 19th
ncologic cause of death, constituting 1.0% of cancer mor-
ality. Standardized mortality is 2.6 in males and 0.3 in
emales.
In males, standardized incidence decreased constantly
etween 1980 and 2005 (−2.7 % p.y. on average), and more
trongly toward the end of that period (−4.7 % p.y. between
000 and 2005). Thus, incidence halved between 1980 and
005, from 14.3 to 7.1. The number of new cases, however,
ell by only 30%, due to population aging. In parallel, the
isk of laryngeal cancer fell from 1.7% for the 1920 cohort
o 1.0% for the 1940 cohort.
In females, standardized incidence is much lower than in
ales and regularly increased, by a mean 2.1% p.y., between
980 and 2005. Part of this increase was probably due to
he increase in female smoking, following the male pattern
ith a certain delay. Other factors, however, may also be
mplicated, and notably the increased frequency of infection
y HPV-type viruses, thought to be involved [4,5].
isk factors
he main risk factor in vocal fold cancer is smoking [6]. Vari-
us elements are involved, and notably local irritation due to
ertain components of tobacco smoke and chronic burning.
he main carcinogens contained in smoke are polycyclic aro-
atic hydrocarbons and nitrosamines. These hydrocarbons
re degraded by certain enzymes (e.g., aryl hydrocarbon
ydroxylase) into carcinogenic compounds. The enzymes in
e
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uestion are genetically determined, which goes some way
o explaining the individual variations found in susceptibility
o the carcinogenic potential of smoking [3].
Alcohol is less implicated in vocal fold cancer than in
ther laryngeal and extralaryngeal locations. The risk, how-
ver, is indisputably increased by association with smoking
50% of glottic cancers) and increases linearly with consump-
ion. No particular form of alcoholic drink (spirits, wine,
eer) seems to be especially implicated [6]. In non-smokers,
he association with alcohol is harder to determine. A multi-
enter case/control study (Italy, Spain, Switzerland, France)
eported an odds ratio of 1.7 in 9 endolaryngeal cancers in
on-smokers with alcohol consumption exceeding 80 g/day
7]. These cases also implicated the malnutrition associated
ith alcohol abuse as inducing carcinogenesis. Other impli-
ated factors were pharyngolaryngeal reﬂux, HPV and HSV
2,3,8]. These risk factors are hard to assess individually
ue to the frequent association with smoking; like alcohol,
owever, they act on mucosal irritation and inﬂamma-
ion, promoting penetration by the carcinogens contained
n smoke. HPV has been much less frequently implicated
n laryngeal than oropharyngeal oncogenesis, but epidemio-
ogical studies have suggested a moderate association with
erotypes 16 and 18 [9]. Recurrent vocal fold papillomato-
is, on the other hand, involves an estimated 1—3% risk of
ransformation into squamous cell carcinoma [5], requiring
ifetime surveillance.
Laryngeal cancer was found to be elevated in non-
moking non-drinking workers exposed to silica and
olycyclic aromatic hydrocarbons or to asbestos, nickel
apor, or textile or coal dust [2,3,10,11]. There is, how-
ver, no ofﬁcial recognition of these work-related laryngeal
ancers.
Finally, the concept of precancerous lesions (leukoplakia,
eratosis, papillomatosis) is real, and they frequently pre-
xist; more often, however, vocal fold cancer develops on
ealthy mucosa [3].
natomopathology
recancerous lesions
recancerous status of the vocal folds refers to epithelial
esions preceding invasive carcinoma. Clinically, they come
nder chronic laryngitis; histologically, the aspect is of alter-
tion ranging from simple hyperplasia to carcinoma in situ,
eferred to as dysplasia [3,12].
Precancerous states feature cellular abnormalities
increased nucleo-cytoplasmic ratio, more numerous
itoses) and structural alterations (dyskeratosis sites,
rregular cell stratiﬁcation) spreading within the epithe-
ium. The basal membrane remains intact. Etiological
actors are as in invasive carcinoma (above).
Several endoscopic aspects are found. Red laryngitis,
ith predominant inﬂammatory phenomena, is distin-
uished from white laryngitis, also known as keratosis due
o the keratinization of the mucosal surface [3].Red laryngitis takes three forms: (i) catarrhal or hyper-
mic laryngitis features diffuse hyperemia of the larynx;
ii) erythroplakia or hypertrophic laryngitis involves thick-
ning and diffuse hyperemia of the laryngeal mucosa; and
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(iii) pseudo-myxomatous hypertrophic laryngitis, or Reinke’s
edema, features a translucent edematous vocal fold aspect.
White laryngitis also comes in three forms: (i) leukoplakia
is not sharply contoured, with ﬂat, pearly white or gray,
candle-wax-like lesion; (ii) white exophytic laryngitis has a
gray or chalky tumoral aspect, with clear exophytic contours
(iii) wharty plaque presents as a grayish or pinkish granular
mass that is strongly exophytic, with spicules. The distinc-
tion between wharty plaque and exophytic leukoplakiais,
however, usually made on histology.
Invasive squamous cell carcinoma
Malpighian carcinoma accounts for about 90% of all glot-
tic tumors, most being well or moderately differentiated
forms.
Verrucous carcinoma presents as a broadly implanted
papilloma [13]. Histologic diagnosis is difﬁcult as biopsy is
often too superﬁcial. These tumors tend to extend locally,
destroying neighboring structures. They do not produce
metastases, but may transform into true malpighian carci-
nomas, thereby acquiring metastatic potential.
Spindle-cell carcinoma is a true squamous cell carcinoma
associating malignant epithelial cells and mesenchymatous-
type cells. It has a polypoid aspect, and a high risk of
metastasis [3].
Rare tumors
Glandular tumor, sarcoma, lymphoma and neuroendocrine
tumor are exceptional in the vocal folds.
Modalities of extension
Extension may be local or metastatic. Tumors generally
develop from the free edge of the vocal folds. When
they invade anatomic subunits having lymphatic vascu-
larization, the risk of lymph-node metastasis increases
[14].
There are also points of resistance and of weakness in the
larynx, which can shed light on and help to assess the risks
of local invasion [2].
Points of resistance:
• to extralaryngeal extension:
◦ thyroid and cricoid cartilage,
◦ hyoepiglottic membrane,
◦ thyrohyoid membrane;
• to intralaryngeal extension:
◦ elastic cone.
Points of weakness:
• to extralaryngeal extension:
◦ anterior commissure (mucosa very close to cartilage)
and back of the ventricle, near the border of the larynx,
◦ cricothyroid membrane;
• to intralaryngeal extension:
◦ paraglottic space (supra- and subglottic extension),
◦ hyothyroepiglottic space (upward extension) from the
cribriform oriﬁces of the epiglottis and the thy-
roepiglottic ligament.
i
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Extension in area may be:
forward, toward the anterior commissure then to the con-
tralateral fold,
backward, toward the frequently invaded arytenoid car-
tilage,
outward, toward the ventricle ﬂoor, secondarily reaching
the back of the ventricle then, upward, the ventricular
band,
downward, toward the inferior side of the vocal fold, then
toward the subglottis.
Extension in depth may be:
lateral and downward, after elastic cone inﬁltration,
toward the paraglottic space then across the cricothyroid
membrane,
lateral and upward, to the inferior thyroarytenoid muscle
(lateral part) and paraglottic space.
NM classiﬁcation (AJCC/UICC TNM, 7th edition,
009) [15]
he International Union Against Cancer (UICC) classiﬁcation
escribes degree of extension according to tumoral progno-
is. A tumor (T) is subject to the following invasions:
Tis: carcinoma in situ;
T1: tumor limited to vocal folds with normal mobility,
liable to invade the anterior or posterior commissure;
◦ T1a: one fold,
◦ T1b: two folds;
T2: tumor extending to the supra- or subglottic levels,
with or without impaired vocal fold mobility;
T3: vocal fold ﬁxation and/or;
◦ invasion of paraglottic space and/or,
◦ invasion of the inner cortex of the thyroid cartilage;
T4a: invasion of thyroid cartilage, trachea, cervical soft
tissue, tongue muscles, subhyoid muscles, thyroid, esoph-
agus;
T4b: invasion of prevertebral space, mediastinal struc-
tures, carotid artery.
TNM may be preﬁxed as cTNM (clinical), pTNM (anato-
opathological), mTNM (primitive multiple tumor), rTNM
recurrent), or yTNM (post-treatment).
This classiﬁcation includes the changes made in the sixth
dition (2002) to the ﬁfth (1997). Radiologic invasion of
he paraglottic space without impaired laryngeal mobility
s classiﬁed as T3. Invasion of the inner cortex of the thyroid
artilage is classiﬁed as T3, and invasion of the outer cortex
s T4.
iagnosis
resenting signs
iagnosis is usually made following dysphonia which is ﬁrst
ntermittent then persistent and growing progressively more
evere [16]. Onset may be hard to determine on interview,
s patients are often still active smokers, hence with chronic
aryngeal inﬂammation. The dysphonia is initially related to
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efective vibration in the vocal fold mucosa, aggravated by
nvolvement of the vocal ligament and muscle (T1) impair-
ng vocal fold mobility (T2). Vocal fold ﬁxation is a sign of
nvolvement of a cricoarytenoid unit (T3).
At a more advanced stage, laryngeal ﬁxation, subglot-
ic invasion and tumor volume may cause dyspnea. Onset of
ysphagia and reﬂex otalgia suggests invasion of the supra-
lottic area and pharynx.
Lymph-node extension is mainly found in evolved (T3, T4)
umor.
linical examination
s smoking is almost always associated, a full patient
nterview is needed to assess general health status and
omorbidity.
The entire upper aerodigestive tract should be carefully
xamined to visualize the primary tumor and any secondary
ocation. The larynx is ﬁrst examined using a mirror or ﬂexi-
le endoscope. A diagram, with date, is used to record tumor
olume, invaded structures and laryngeal mobility. Tumors
mpairing vocal fold mobility are classiﬁed as T2 (T2b for cer-
ain authors) whereas arytenoid ﬁxation is classiﬁed as T3.
o complete the ENT examination, the cricoid and arytenoid
artilage as well as the hyothyroepiglottic space should be
alpated.
araclinical assessment
araclinical assessment comprises extension assessment,
xploration for synchronous tumor, nutritional assessment
nd pretreatment check-up [17].
xtension work-up
adiological assessment. Cervicothoracic CT scan is per-
ormed with and without contrast enhancement, with
ustained dynamic maneuver using /e/ if possible, to
pproximate the vocal folds and visualize their entire
ength, and Valsalva maneuver to expose the piriform
inuses. Notably, it assesses any tumor extension from the
ocal fold to the anterior commissure, paraglottic space,
yothyroepiglottic space, laryngeal cartilage or lymph-node
reas. Thoracic CT explores for any synchronous pulmonary
ocation or mediastinal or pulmonary metastasis.
Laryngeal MRI provides more detailed analysis of soft
issue and non-calciﬁed cartilage [18]. Interpretation, how-
ver, is harder than for CT: images are often of uneven
uality due to swallowing movements. Sensitivity is good but
peciﬁcity mediocre, as the signal does not distinguish tumor
rom simple inﬂammation, in any of the various sequences
nd whether the laryngeal cartilages are ossiﬁed or not. The
arynx is all the more difﬁcult to assess following radiation
herapy in case of persistent inﬂammation. MRI is there-
ore not usually undertaken in current practice. Becker et
l., however, drew up new diagnostic criteria for cartilage
nvasion: in case of tumor invasion, the signal will be iden-
ical between tumor and invaded cartilage, while in case
f inﬂammation the signal is higher than in the tumor for
equences T2 and T1 under gadolinium enhancement [19].
Abdominal ultrasound scan explores for signs of cirrhosis
r liver metastasis.
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PET-CT scan should explore evolved tumor for metasta-
is or secondary location ahead of any indication for heavy
urgery, especially following radiation therapy or in revision
urgery.
NT panendoscopy and suspension laryngoscopy. Rigid
ndoscopy is performed under general anesthesia following
he paraclinical extension assessment. Before intubation,
0◦ or even better 70◦ rigid endoscopes are used, to
btain good visualization of the ventricles, anterior commis-
ure and subglottic region. After intubation, assessment
egins with exploration for any secondary location by rigid
sophagoscope (exploration of hypopharynx and esophagus
o 25—30 cm from the dental arches), pharyngoscopy and
xamination of the base of the tongue.
Suspension laryngoscopy allows microscopic examination
f the cordal lesion and assessment of the possibilities for
aryngeal exposure. It also allows tumor biopsy and demar-
ation biopsies of the glottis to contour the lesions ahead
f endoscopic surgery. Biopsy resection may be performed
irectly by type-1 laser cordectomy after hydrodissection if
he lesion is well deﬁned and does not go trough the mucosa.
nvestigation to explore for synchronous tumor
ertain authors recommend systematic bronchial ﬁbroscopy
n case of history of smoking. It can detect tumors not visu-
lized on thoracic CT.
Assessment may be completed by esogastric ﬁbroscopy to
xplore for lower esophageal or stomach tumor or for gastric
lcer, hiatus hernia or Barret’s esophagus.
omplementary examinations
utritional assessment. Nutritional status should be
ssessed ahead of any treatment, whether surgery, radiation
herapy or chemotherapy, and indeed determines treatment
nitiation. The Buzby index, based on weight loss and albu-
in level, quantiﬁes denutrition, and is more precise than
ody-mass index (BMI), as it is possible for obesity (BMI >30)
nd denutrition to be associated.
The Buzby or Nutritional Risk Index (NRI) is calculated on
he following formula:
NRI = 1.519× albuminemia− 0.417×% variation in nor-
al weight (N.B.: edema can mask weight-loss). Three
ategories are deﬁned:
NRI > 97.5: no denutrition;
83.5 <NRI < 97.5: moderate denutrition;
NRI < 83.5: severe denutrition.
reoperative assessment. Preoperative assessment com-
rises:
complete biological assessment: liver function tests, iono-
gram, urea, creatinine, coagulation, full blood count;
cardiac assessment: EKG, echocardiogram possibly asso-
ciated to: lung function tests, especially in case of partial
laryngeal surgery.ssessment before radiation therapy. Dental check-up:
onsultation + orthopantomogram.
ssessment before chemotherapy. Assessment of nutri-
ional status, renal function, cardiac function.
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Figure 2 Vocal fold structure (a: epithelium; b + c + d = lamina
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Therapeutic management of glottic cancer
This section focuses on T1 vocal fold cancer. Treatments for
other stages are simply mentioned or gone into brieﬂy.
Multidisciplinary team meeting
A multidisciplinary coordination meeting is mandatory
ahead of treatment. Ideally, it brings together the
ENT surgeon, radiation therapist, chemotherapist, anato-
mopathologist, radiologist and psychologist.
Medical history, extension assessment, pretherapeutic
assessment and the patient’s lifestyle are collated so as
to optimize the efﬁcacy/quality-of-life ratio. A dedicated
form, detailing those present at the meeting, the patient’s
and primary care physicians’ contact details, the various
assessments and any inclusion in therapeutic trials is ﬁlled
out and sent to the family doctor with a copy kept in the
clinical ﬁle. Treatment options are based on the guidelines
[20] drawn up from national and international recommen-
dations. At the end of the meeting, the attending physician
for the pathology, with or without other care team mem-
bers, explains the treatment options to the patient clearly
and in detail so as to inform his/her decision and draw up
an individual treatment program.
Surgical treatment
Cordectomy (European Laryngological Society
classiﬁcation)
Transoral cordectomy generally uses CO2 laser under sus-
pension laryngoscopy with operative microscope [3,21—23].
Cordectomy on an external approach, also known as laryn-
goﬁssure, is only exceptionally performed. When endoscopic
exposure of the glottis is not feasible, radiation therapy
provides an equally effective alternative to surgery [24].
Cordectomy is indicated in precancerous lesions, Tis, T1a,
T1b or in some cases T2.
Subepithelial cordectomy or decortication (type I). Sub-
epithelial cordectomy or decortication (type I) consists
in resecting the epithelium and superﬁcial lamina propria
(Reinke’s space, Fig. 2). It is indicated in precancerous
lesions and in situ carcinoma when mucosal vibration
is unimpaired on videostroboscopy and hydrodissection
between mucosa and vocal ligament can be performed by
physiological saline injection.
Subligamentary cordectomy (type II). Subligamentary
cordectomy (type II) concerns the epithelium, the various
lamina propria layers and most superﬁcial ﬁbers of the vocal
muscle. It is indicated in case of microinvasion or in case
of doubt as between simple in situ carcinoma and focally
inﬁltrating carcinoma.
Transmuscular cordectomy (type III). Transmuscular
cordectomy (type III) involves resecting the epithelium,
lamina propria and part of the vocal muscle. The ventricular
band may need to be partially resected to expose the vocal
muscle correctly. This procedure is indicated in superﬁcial
T1a tumor limited to the mid-third of the vocal fold.
Total cordectomy (type IV). Total cordectomy (type
IV) extends from the vocal apophysis to the anterior
commissure, involving the entire vocal fold and internal
b
r
A
uropria; b: superﬁcial layer; c: intermediate layer; d: deep
ayer; e: vocal muscle).
erichondrium of the thyroid ala. It is indicated in can-
er invading the vocal muscle, inducing radiologic signs or
mpaired vocal fold mobility.
nlarged cordectomy (type V). Enlarged cordectomy
type V) extends either to the anterior commissure and
ontralateral fold (Va), or to the arytenoid (Vb), subglot-
is (Vc) or ventricle (Vd). It is indicated for T1a to T2 tumors
and T3 according to certain authors). Particular attention
s needed in case of tumor impairing vocal fold mobility, ini-
ially classiﬁed as T2 but which may turn out to be T3 due
o invasion of the paraglottic space, in which case the onco-
ogical results of this procedure may be very disappointing.
ype VI cordectomy. Type VI cordectomy is indicated in
nterior commissure cancer whether or not extending to one
r both vocal folds, without thyroid cartilage inﬁltration. It
equires resecting the epiglottic petiole, the anterior part
f the ventricles and vocal folds, the anterior commissure
nd downstream subglottic mucosa or even the cricothy-
oid membrane and anterior angle of the thyroid cartilage
25—27].
artial surgery on an external approach
ertical hemilaryngectomy. Vertical hemilaryngectomy,
onsisting in monoblock resection of the tumoral vocal fold,
nterior commissure, anterior part of the contralateral fold
nd a fragment of thyroid cartilage, is indicated in T1a
umor. Endoscopic laser surgery is nowadays usually pre-
erred, or external radiation therapy if laryngeal exposure
s not satisfactory.
nterior frontal laryngectomy with Tucker epiglottoplasty.
nterior frontal laryngectomy with Tucker epiglottoplasty
s indicated in T1—T2 tumor of the anterior glottis. Resec-
ion involves the anterior two-thirds of the thyroid cartilage,
ut may extend to an entire vocal fold up to the arytenoid,
emoving the anterior two-thirds of the contralateral fold.
fter transepiglottic horizontal laryngotomy, the ventric-
lar band, vocal ligament and thyroarytenoid muscle are
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ertically sectioned anteriorly to the arytenoid cartilage
vocal process) up to the cricoid cartilage. Reconstruction
onsists in lowering the epiglottis and suturing it onto the
uperior edge of the cricoid cartilage [26].
upracricoid laryngectomy. Supracricoid laryngectomy
ith cricohyoidoepiglottopexy (CHEP) or cricohyoidopexy
CHP) is indicated in T2—T3 tumor:
with glottic and ventricular involvement with or without
vocal fold ﬁxation (without arytenoid cartilage ﬁxation);
involving the paraglottic space and/or internal perichon-
drium of the thyroid cartilage;
involving (CHP) or not (CHEP) the pre-epiglottic space.
These laryngectomy procedures conserve the hyoid bone,
ricoid cartilage and at least one arytenoid cartilage. They
acriﬁce the thyroid cartilage, vocal folds and ventricular
ands, along with the epiglottis (CHP) or not (CHEP) [26].
otal laryngectomy
otal laryngectomy is indicated in T3 and T4 glottic tumor
r T2 tumor with subglottic extension.
reatment of lymph-node areas
ymph-node groups being only rarely invaded by T1 tumors,
eck dissection is not recommended. In T2—T3 glottic tumor,
eck dissection of levels II, III and IV is usually performed,
psilaterally or bilaterally in case of suspected multiple ipsi-
ateral adenopathy and/or > 3 cm adenopathy or suspected
ontralateral adenopathy. In stage T4, uni- or bilateral
esection of levels II, III, IV, V and VI is standard practice
20].
adiation therapy
xclusive radiation therapy may be indicated in T1 and small
2 glottic tumor [28].
So long as the lesion is strictly glottic, radiation involves
nly the target tumor volume, as these lesions show very low
ymphophilia, and is usually performed with two opposing
× 5 cm or 6× 6 cm parallel ﬁelds. In case of supraglottic
xtension, radiation can be extended to lymph-node areas
I, III and IV, and to VI a and b in case of subglottic extension.
The dose to the tumor ranges from 60 to 70 Gy, depending
n tumor stage, in 2Gy fractions. A dose of 66Gy is usually
elivered for Tis and T1 tumors and 70Gy for T2. In lymph-
ode areas, dose ranges from 50Gy in prophylactic radiation
o 60—70Gy in clinically invaded areas.
In some cases (T2), concomitant 5-Fluorouracil and platin
hemotherapy may be used.
Intensity modulated radiation therapy (IMRT) is indicated
n larger radiation ﬁelds to modulate the dose received and
pare certain tissues (e.g., parotid glands). It is thus of little
nterest in T1—T2 tumors.
hemotherapyhemotherapy is used in T3 and T4 tumor and/or
hen resection margins are positive and/or in case of
etastatic extracapsular adenopathy extension. InductionP. Schultz
hemotherapy may be considered in a laryngeal conserva-
ion program, if there is no massive invasion of laryngeal
artilage [29]; it associates 2—3 cycles of TPF (tax-
nes, platins, 5 FU) and, depending on response (> 50%,
aryngeal remobilization), is followed by concomitant cura-
ive chemoradiotherapy. Primary sequential or concomitant
hemoradiotherapy is reserved for patients who refuse total
aryngectomy and cannot beneﬁt from induction chemother-
py, or for inoperable tumor.
Exclusive chemotherapy comprising cisplatin and 5-
uorouracil was performed in certain patients initially
reated by induction chemotherapy. Holsinger et al.
eported a series of 142 patients presenting with T1—T4
aryngeal or pharyngeal squamous cell carcinoma [30]. The
atients had shown total response to two or three courses
hen either refused complementary radiation therapy or
urgery or else underwent simple surveillance in an exclusive
hemotherapy protocol. Most of those included, and the best
esults in terms of local control, concerned glottic cancer,
here 5-year survival was 61%, with deaths associated with
etachronous tumor (n = 27), intercurrent disease (n = 21),
ocal or lymph-node recurrence or remote metastasis. This
reatment option is, however, still under study and cannot
s yet be considered in routine practice.
ndoscopic surgery versus radiation therapy: pros
nd cons
any retrospective studies have reported equivalent results
or endoscopic surgery and radiation therapy in terms of
ocal control, laryngeal conservation and survival in T1 vocal
old cancer. Each, however, has its advantages and draw-
acks [24,31]:
Laser cordectomy:
◦ advantages:
— reproductible in case of recurrence; possibility of
2nd-line radiation therapy in case of recurrence or
of second location,
— anatomopathologic control,
— feasible in case of prior radiation therapy,
— lower cost,
— short hospital stay;
◦ Drawbacks
— vocal quality less satisfactory than with radiation
therapy overall (level of evidence D: no randomized
studies, especially concerning the different types of
cordectomy),
— general anesthesia,
— laryngeal exposure can be difﬁcult, and difﬁculty of
large-scale anterior commissure resection;
Radiation therapy:
◦ advantages:
— better vocal quality;
◦ Drawbacks:
— edema and laryngeal inﬂammation,
— sensation of dry larynx,
— to 8 weeks’ treatment duration,
— more expensive than surgery,
— difﬁcult or impossible in ulterior pharyngolaryngeal
locations.
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Choice thus depends on the care-team’s experience and
that of the patient (treatment choice), on laryngeal expo-
sure, the feasibility of general anesthesia and on the type of
cordectomy concerned. Postcordectomy voice quality varies
with the scale of resection. From submucosal (type I) to
transmuscular (type III) cordectomy, there is little impact
on the normal speaking voice. Total or extensive cordectomy
induces dysphonia, especially when the anterior commissure
is resected, in which case formation of a synechia leads to
a compensation mechanism basically in the form of false
vocal-cord voice.
Prognosis
Whatever the treatment (cordectomy or radiation therapy),
teams with good oncological experience report 85—95% 5-
year local control in T1 tumor, with identical rates of
laryngeal conservation and of speciﬁc survival [17].
Five-year local control in T2 tumor ranges from 60 to 94%.
Results are less satisfactory with radiation therapy (60—85%)
[32], especially when applied to thick tumor involving the
anterior commissure or in case of impaired vocal fold mobil-
ity. Partial surgery with an external approach provides
70—94% [33,34] and CO2 laser surgery 70—85% local con-
trol. Final control rates after revision surgery range from 85
to 99%. Speciﬁc survival is broadly comparable between the
various treatment modalities, at 90—95%. Absolute 5-year
survival is 60—80%, with 20% of deaths due to intercurrent
pathology.
In more advanced tumors, prognosis depends more on
tumor stage and lymph-node status than on tumor size itself.
In stage 3, absolute survival is 50—60%, falling to 30—40% in
stage 4 [35—37], the most frequent cause of death being
metastasis [35]. The most effective treatment consists of
surgery followed by radiation therapy, associated or not to
postoperative chemotherapy. Organ conservation protocols,
according to certain authors [38], provide results in terms of
survival and local control that are comparable to reference
surgical procedures, while others reported reduced overall
survival [39].
Follow up
Follow up is clinical, biological and radiological, following a
precise schedule or responding to clinical events [40].
Clinical surveillance comprises interview (symptoms,
psychological status, intoxications), clinical ENT examina-
tion, dental examination, weight monitoring and general
health assessment. It is performed every 2months during the
ﬁrst year, every 3months the second year, every 4months
the third year, then every 6months up to the ﬁfth year.
If smoking and alcohol consumption continue, surveillance
continues every 6months after the ﬁfth year. Radiolog-
ical surveillance comprises lung X-ray at 6months then
yearly. The incidence of metachronous tumor in glottic
cancer is 2—3% per year, depending of the report [41,42]
and on persistence of smoking. Onset of another tumor
location is twice as common as in the general population
[42]. The most frequent locations are, in descending order,
the upper aerodigestive tract, lung, esophagus, prostate,
colon-rectum and urinary tract [41—43]. TSH is titrated
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early in case of thyroid gland irradiation or of hemithy-
oidectomy.
onclusion
creening and treatment of upper aerodigestive tract cancer
eek to maximize survival and minimize sequelae. Early dys-
honia and low lymphophilia give vocal fold cancer the best
rognosis among upper aerodigestive tract cancers. Diagno-
is, clinical and paraclinical assessment and treatment are
ell codiﬁed. Whatever the treatment choice, cessation of
moking, speech therapy, close surveillance and prevention
f cardiovascular risk factors are strongly recommended. In
1—T2 tumor, such good health practices improve comfort
f life and limit onset of the other pathologies which are the
ajor cause of death.
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